论文部分内容阅读
通过观察23例伴t（8；21）的急性粒细胞白血病临床表现、血液学异常、AML1－ETO融合基因及治疗效果，结果显示：AML1－ETO融合基因可作为急性粒细胞白血病M3b的分子标志物；本组病例完全缓解率61％，疗效与其他类型急性白血病相似；肝脾肿大是预后不良因素之一。
By observing the clinical manifestations, hematological abnormalities, AML1-ETO fusion gene and therapeutic effects of 23 patients with acute myeloid leukemia with t(8;21), the results showed that: AML1-ETO fusion gene can be used as a molecular marker of acute myeloid leukemia M3b In this group of patients, the complete remission rate was 61%, and the curative effect was similar to other types of acute leukemia; hepatosplenomegaly was one of the poor prognosis factors.